These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736 [TBL] [Abstract][Full Text] [Related]
28. GPR120 agonists for the treatment of diabetes: a patent review (2014 present). Zhang X; Macielag MJ Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609 [TBL] [Abstract][Full Text] [Related]
29. Structure-Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists. Zhao X; Yoon DO; Yoo J; Park HJ J Med Chem; 2021 Apr; 64(7):4130-4149. PubMed ID: 33769827 [TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751 [TBL] [Abstract][Full Text] [Related]
31. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats. Gowda N; Dandu A; Singh J; Biswas S; Raghav V; Lakshmi MN; Shilpa PC; Sunil V; Reddy A; Sadasivuni M; Aparna K; Verma MK; Moolemath Y; Anup MO; Venkataranganna MV; Somesh BP; Jagannath MR BMC Pharmacol Toxicol; 2013 May; 14():28. PubMed ID: 23692921 [TBL] [Abstract][Full Text] [Related]
32. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Mancini AD; Poitout V Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916 [TBL] [Abstract][Full Text] [Related]
33. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation. Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366 [TBL] [Abstract][Full Text] [Related]
34. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Briscoe CP; Peat AJ; McKeown SC; Corbett DF; Goetz AS; Littleton TR; McCoy DC; Kenakin TP; Andrews JL; Ammala C; Fornwald JA; Ignar DM; Jenkinson S Br J Pharmacol; 2006 Jul; 148(5):619-28. PubMed ID: 16702987 [TBL] [Abstract][Full Text] [Related]
35. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289 [TBL] [Abstract][Full Text] [Related]
36. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists. Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985 [TBL] [Abstract][Full Text] [Related]
37. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats. Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664 [TBL] [Abstract][Full Text] [Related]
38. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships. Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791 [TBL] [Abstract][Full Text] [Related]
39. Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40). Rodrigues DA; Pinheiro PSM; Ferreira TTDSC; Thota S; Fraga CAM Chem Biol Drug Des; 2018 Mar; 91(3):668-680. PubMed ID: 29068547 [TBL] [Abstract][Full Text] [Related]
40. Modulating GPR40: therapeutic promise and potential in diabetes. Poitout V; Lin DC Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]